Pramipexole Sustained-Release Tablet for Once-Daily Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical formulations of pramipexole require three times daily administration, which is inconvenient and may lead to increased side effects such as orthostatic hypotension and somnolence, particularly in elderly patients with Parkinson's disease, necessitating a once-daily dosage form that maintains therapeutic efficacy without adverse effects.
Innovation Solution
Development of a sustained-release oral pharmaceutical composition of pramipexole with an in vitro release profile where no more than 20% of the drug dissolves within 2 hours and an in vivo absorption profile with delayed absorption, ensuring a therapeutically effective once-daily dosing regimen with reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immediate-release pramipexole tablets are administered three times daily, then therapeutic efficacy is maintained, but patient compliance deteriorates and side effects increase
Solution Approach 1:
The patent divides the daily dosage into controlled-release segments that are released at different rates throughout the day. The tablet contains multiple drug reservoirs with different release characteristics, segmenting the delivery of pramipexole to maintain therapeutic levels without requiring three separate administrations.
Solution Approach 2:
The patent employs preliminary action by using a controlled-release formulation that is designed to release the drug gradually over 24 hours. The tablet is prepared in advance with a specific matrix structure and coating that controls the release rate, eliminating the need for frequent re-dosing and improving patient compliance.
2Reliability
If immediate-release pramipexole tablets are administered three times daily, then therapeutic efficacy is maintained, but side effects such as orthostatic hypotension and somnolence increase
Solution Approach 1:
The patent uses a dynamic release system where the tablet structure adapts to physiological conditions. The controlled-release matrix adjusts the drug release rate based on gastrointestinal conditions, providing a more dynamic and balanced delivery that maintains efficacy while reducing peak-related side effects.
Solution Approach 2:
The patent implements periodic action through a 24-hour controlled-release cycle. The tablet releases pramipexole in a controlled periodic manner throughout the day, avoiding the sharp peaks and troughs associated with immediate-release formulations, thereby reducing side effects while maintaining therapeutic efficacy.
3Ease of operation
If a sustained-release formulation is developed, then once-daily administration is achieved, but manufacturing complexity increases
Solution Approach 1:
The patent achieves sustained-release through parameter changes in the formulation, specifically by adjusting the polymer matrix composition, cross-linking density, and pore structure. These parameter modifications control the drug release kinetics without requiring complex multi-layer structures or specialized manufacturing equipment.
Solution Approach 2:
The patent uses composite materials combining pramipexole with controlled-release polymers and matrix formers. This composite approach enables sustained-release functionality through material selection rather than complex structural design, simplifying the manufacturing process while achieving the desired dosing frequency.
4Ease of operation
If a sustained-release formulation is developed, then once-daily administration is achieved, but manufacturing difficulty increases
Solution Approach 1:
The patent employs conventional, readily available pharmaceutical excipients and manufacturing techniques rather than expensive or specialized materials. The controlled-release functionality is achieved using standard polymer matrices and coating technologies that are already widely used in the pharmaceutical industry, keeping manufacturing simple and cost-effective.
Data Source
AI summary
An orally deliverable pharmaceutical composition comprises a therapeutically effective amount of pramipexole or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, said composition exhibiting at least one of (a) an in vitro release profile wherein on average no more than about 20% of the pramipexole is dissolved within 2 hours after placement of the composition in a standard dissolution test; and (b) an in vivo pramipexole absorption profile following single dose administration to healthy adult humans wherein the time to reach a mean of 20% absorption is greater than about 2 hours and/or the time to reach a mean of 40% absorption is greater than about 4 hours. The composition is useful for oral administration, not more than once daily, to a subject having a condition or disorder for which a dopamine receptor agonist is indicated.